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Abstract
Objective: The focus of this study is to share the experience and outcomes of Contegra graft implantation in the
paediatric and adult population in Pakistan.
Methods: Between May 2007 and July 2011, 16 patients, underwent implantation of a Contegra valved conduit.
All operations were performed through a median sternotomy with cardiopulmonary bypass. Indications included:
Pulmonary atresia with ventricular septal defect (n=11), Tetralogy of Fallot with absent Pulmonary Valve (PV)
syndrome (n=2), double outlet right ventricle, transposition of great arteries and pulmonary stenosis (n=1),
isolated aortic valve disease (n=1) and a pseudo-aneurysm with infective endocarditis (n=1).Conduit sizes varied
between 16-22 mm.
Results: The three in hospital deaths were unrelated to the Contegra valved conduit. One patient was lost to
follow up. Of the 12 survivors, 10 are currently free from re-operation or complications related to the conduit while
one needed distal pulmonary artery dilatation owing to critical stenosis and another had severe Valvular
regurgitation. Echocardiographic evaluation of the Contegra valved conduit demonstrated no haemodynamically
significant valve regurgitation in 10 patients.
Conclusion: In this small review of 16 operations using the Contegra valved conduit for Right Venticular Outflow
Tract (RVOT) reconstruction in the paediatric population, we observed good post operative results concerning
conduit function. The Contegra conduit provides an excellent substitute to the homograft with satisfactory early
and mid-term results though long term results are awaited in Pakistan.
Keywords: Contegra conduit, Right ventricle to pulmonary artery reconstruction, Echocardiography.
(JPMA 62: 1113; 2012).

Introduction

conduit at the Aga Khan University Hospital, Karachi,
Pakistan.

The unavailability of homografts has led to a rising
demand for conduits for right ventricular outflow tract
(RVOT) reconstruction surgery. Xenografts and synthetic
grafts have been far from ideal, with increasing long term
complications prompting the search for alternatives. One
such option is the Contegra (Medtronic Inc., Minneapolis,
MN), a biological valved conduit consisting of a
heterologous bovine jugular vein with a tri-leaflet valve
preserved in glutaraldehyde. Introduced in 1999, it has
emerged as a strong contender in RVOT reconstruction
surgery. Various studies have been conducted on the clinical
outcomes of the conduit in both paediatric and adult
population, yielding favourable results.1,2

This is a retrospective study of an operative
technique conducted at the Aga Khan University Hospital
from May 2007- July 2011. The data was gathered from
March - June 2011. Demographic variables included age,
sex distribution, weight, diagnosis, operative techniques,
complications and post-operative echocardiographic
analysis and length of follow-up. Data was analyzed using
the SPSS for Windows (version 17.0) and is expressed as
median and minimum and maximum ranges where
appropriate. No statistical tests were applied to the data.

The aim of this study is to share the surgical
experience and results of implanting the Contegra valved

All operations were performed via a median
sternotomy. The initial dissection to free the pulmonary
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arteries and its branches was done prior to establishing
cardiopulmonary bypass (CBP). If there were major aortopulmonary collateral arteries (MAPCA's) they were also
initially dissected free to be ligated or implanted later while
on CPB. Cardiopulmonary bypass was established with
aortic and bi-caval cannulation and moderate hypothermia
of 28°C.
Aortic cross-clamping was applied and myocardial
preservation was maintained with intermittent antegrade
cold blood cardioplegia for intra-cardiac repair. The VSD
was closed with a patch of Dacron usually through a right
atriotomy and through the tricuspid valve along with the
right ventriculotomy where the proximal end of the
Contegra grafts anastomosis was to be fashioned. The
Contegra graft was then trimmed to size, with the valve
positioned as close to the distal anastomosis as possible.
The lie of the Contegra was to the left so that it did not come
to lie directly under the sternum. The pulmonary artery was
then transected and proximal end transfixed if required.
The pulmonary arteriotomy was extended onto the
branch pulmonary artery (PA) with extension into the left
pulmonary artery (LPA). This defect was then closed with a
patch of Contegra to increase the size of the PA and also to
provide a tension free anastomosis away from the delicate
pulmonary artery wall. The distal anastomosis between the
Contegra and patch on the PA was fashioned with Prolene 50 or 4-0 depending on the size of the patient. It was made
sure that there was intimal contact but avoided full thickness
bites of the Contegra and its patch as the external wall is
thick and rough which may later lead to later stenosis. The
proximal end was then anastomosed to the right ventricle
(RV) in a way that a hood is created. If there was a lack of
a hood, a patch of bovine or gluteraldehyde treated
autologous pericardium was utilized (Figure). The

atriotomy was closed during re-warming. A PFO was
always left behind to vent the RV and maintain cardiac
output in the setting of post-operative RV dysfunction.
Post-operative echocardiography was performed in
all patients at time of discharge, measuring maximum
instantaneous gradient across the Contegra and right
ventricular ejection fraction (EF) which was measured by
visual estimation and Simpson's method. Follow up data
was obtained in June 2011, and echocardiography was
performed and maximum instantaneous gradient across the
Contegra were compared to the results at the time of
discharge.

Results
A total of 16 patients (8 males, 8 females) underwent
Contegra valved conduit implantation at the Aga Khan
University Hospital during the period of May 2007-July
2011. Median age at surgery was 6.6 years (range 1.0818.00 years), and median weight was 15.5 kg (range 9.145.0 kg). A 22mm conduit was implanted in 7 patients, a 20
mm conduit in 6 patients, an 18mm in 2 patients and a
16mm conduit in 1 patient.
Indications included pulmonary atresia with
ventricular septal defect (VSD) in 11 patients, Tetralogy of
Fallot (ToF) with absent pulmonary valve syndrome
(APVS) in 2 patients, double outlet right ventricle (DORV),
transposition of great arteries (TGA) and pulmonary
stenosis in 1 patient each, an infected pseudo-aneurysm in 1
patient and aortic valve disease needing a Ross procedure in
1 patient.
The patient presenting with a pseudo-aneurysm had
undergone a Rastelli procedure abroad. Patients with
pulmonary atresia with VSD had also undergone operative

Table-1: Indications and operative procedures.
Group

Patients (n=16)

Primary operation
I
2
Second operation
II
11

Etiology

Previous surgery

Operative Procedure

Tetralogy of Fallot with absent
pulmonary valve syndrome

-

Correction of Fallot's Tetralogy

All patients had pulmonary atresia and
ventricular septal defect with MAPCAS
1 PDA, PFO 1 Hypoplastic conduit

6 patients had undergone a BlalockTaussig shunts+ and 1 a Rastelli
procedure

Rastelli procedure and closure of
interventricular communications

Closure of interventricular
communications+ Atrioventricular repair
Rastelli procedure

Ross procedure

PA-Band, Rastelli DORV, RV-PA conduit

Complete repair

III

1

Isolated aortic valve disease

IV

1

Pseudoaneurysm of RV to PA conduit
with infective endocarditis

V

1

DORV, d-TGA, PS

Replacement of conduit

MAPCAS= major aorto-pulmonary collateral arteries, PDA= patent ductus arteriosus, PFO= patent foramen ovale, TGA= transposition of great arteries, VSD= ventricular septal
defect, DORV= Double outlet right ventricle, RV= right ventricle, PA= pulmonary artery.
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Table-2:
Serial no

1
2
3
4
5
6
7
8
9
10
11
12

Diagnosis

Size of
conduit

Age at
surgery

Follow up
(months)

PA-VSD
PA-VSD
DORV, D-TGA, PS
PA-VSD
ToF-APVS
PA-VSD
PA-VSD
PA-VSD
PA-VSD
PA-VSD
Aortic Regurgitation
TGA, DORV, PA-VSD, infective endocarditis

18
18
20
20
20
20
20
22
22
22
22
22

5.33
5.42
3.17
3.33
5
5.58
11
6.25
10
11
11.83
16

50
25
19
12
50
13
1
39
44
5
11
26

Conduit
Conduit stenosis Conduit
regurgitation
(degree)
aneurysm
moderate
none
none
severe
none
none
none
none
none
none
none
moderate

moderate
severe
none
none
none
none
none
none
none
none
none
moderate

none
none
none
none
none
none
none
none
none
none
none
none

Branch PA
stenosis
none
severe
none
severe
none
none
none
none
none
none
none
none

PA; pulmonary atresia, VSD; ventricular septal defect, DORV; double outlet right ventricle, TGA; transposition of great arteries, APVS; absent pulmonary valve syndrome.

free from any reoperations.
A median midterm follow up corresponded to 22
months (range 1-50 months). One patient was lost to follow
up corresponding to a midterm follow up rate of 92%. At a
22 month follow-up echocardiographic analysis showed 1
patient having severe pulmonary stenosis and 1 had severe
pulmonary regurgitation while 2 had moderate pulmonary
stenosis and regurgitation. There was one re-intervention
(8%) with dilatation of the LPA secondary to stenosis which
was away from the distal conduit anastomosis. There was
no replacement required (Table-2).

Discussion

Figure: The Contegra valved conduit about to be used as a right ventricle to
pulmonary artery conduit.

interventions, usually a Blalock Taussig shunt insertion.
Indications together with previous surgeries are presented in
Table-1.
The median by pass time was 207.5 minutes (range
140-390 minutes) and cross clamp time was 135 minutes
(range 0-215 minutes).
All patients underwent a trans-thoracic
echocardiography measuring maximum instantaneous
gradient across the Contegra of 25mmHg (range 1040mmHg) and a right ventricular ejection fraction of 57.5%
(35-65%). There were no immediate post operative
morbidities and no patient demonstrated any significant
valvular insufficiency. The three early deaths were
secondary to pulmonary haemorrhage, cardiogenic shock
and plastic bronchitis in the three patients and were hence
unrelated to conduit implantation. All remaining patients
experienced no conduit related early morbidity, and were
1115

Right ventricle to pulmonary artery conduits have
made it possible to palliate congenital heart anomalies
including severe Tetralogy of Fallot, truncus arteriosus
(TA), pulmonary atresia with or without ventricular septal
defect (VSD) and transposition of great arteries with VSD
and pulmonary stenosis. First pioneered by Ross et al in
1966,3 the use of a valved homograft conduit for RVOT
reconstruction revolutionized the treatment of right sided
congenital cardiac diseases. This initial success led to the
use of conduits for the correction of TA in 1968,4 and for
transposition with VSD and pulmonary stenosis in 1969.5
And since then, with extensive evolvement and refinement
of congenital cardiac procedures requiring RVOT
reconstruction, the use and demand for conduits especially
in the paediatric population, has increased exponentially.
However, the choice of conduit for RVOT
reconstruction continues to be a challenge. This is because
of the various alternatives available3 which include stented
bovine or porcine xenografts in pericardial tubes,
glutaraldehyde fixed aortic or pulmonary roots, non valved
tissue or prosthetic conduits, bioprostheses in Dacron tubes
and aortic and pulmonary homografts. Amongst all of these,
the debate for the search of an ideal conduit is yet to be
J Pak Med Assoc

settled. The ideal conduit is such that it should be easily
implanted, lack degeneration or the development of
obstruction, allow for growth, be free from insufficiency
and would not require long-term anticoagulation.
Cryopreserved pulmonary and aortic homografts have been
considered the "gold-standard" since the 1980's.6 They are
non-reactive, have a superior durability, are
haemodynamically superior to all other valve prosthetics
and do not necessitate life time anti coagulant therapy.
Amongst the two, pulmonary homografts are preferred
because of their decreased propensity towards obstruction
and calcification.6,7
The credibility of pulmonary homografts is marred
by their diminished supply and restriction in the conduit
sizes (10-18 mm). In addition, early and mid term follow up
results reveal they undergo shrinkage which predisposes to
conduit stenosis and valvular insufficiency. Calcification of
conduit also remains a significant problem.8-11 A prosthetic
material is also necessary on the proximal end to provide an
aid in creating a hood and connection to the right ventricle.
The aforementioned drawbacks led to the search for an
alternate conduit for RVOT reconstruction for the Ross
procedure and congenital heart defects. The Contegra
bovine conduit, introduced in 1999, is one such option.
Early animal studies reported encouraging results with
excellent haemodynamics, satisfactory valvular function,
and absence of any structural degeneration or valve
regurgitation at three years interval.12 Human clinical trials
that followed.13 reaffirmed the claims making Contegra a
front runner in the alternative to homograft conduits.
Subsequently reported experience and outcomes of
Contegra conduit in congenital surgeries and Ross
procedure are increasingly favourable as demonstrated by
various clinical results.14-16 Principal advantages of the
Contegra include a large variety of available sizes (12 to 22
mm internal diameter), 'off the shelf' availability, good
haemodynamics, unique tailoring options and a moderate
cost. Sufficient length is made available at both inflow and
outflow tract to facilitate various reconstructive surgical
procedures. Taken from the venous circulation, the conduit
exhibits the same characteristics of a low pressure
circulation as required for the pulmonary vascular tree.
Some reports claim the haemodynamic performance of the
Contegra in the Ross procedure to be better than that of the
homografts.17,18 The reported complications with Contegra
have been critical dilatation, insufficiency, calcification, and
repeated stenosis in the pulmonary artery region.19-21 The
last has been a significant factor in conduit related failure.
This study describes our surgical experience of the
implantation of the Contegra valved conduit in 16 patients.
In our study, with a limited follow up of 22 months 10
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conduits remained free from any complication. There was
one re-intervention in our series owing to critical stenosis of
the left pulmonary artery just distal to the anastomosis
requiring balloon dilatation. Another patient has severe
pulmonary regurgitation secondary to bilateral distal branch
pulmonary artery stenosis away from the distal conduit
anastomosis. The remaining patients have been of any
findings suggestive of conduit failure due to obstruction,
dilatation and calcification or are in NYHA class I. Brown
et al using a similar technique reported a branch PA stenosis
of 1.5%; another study reported six reoperations in 108
Contegra implantations due to distal pulmonary artery
stenosis.21,22 We determined that the pulmonary artery
should be patched and the Contegra should be anastomosed
to the patch rather than the artery itself. This helps in
avoiding the contact of direct sheer forces on the delicate
pulmonary artery. We also believe avoiding full thickness of
the Contegra in the lumen, as it leads to the development of
a neo-intimal peel at the anastomosed area and maybe a
major cause of conduit obstruction. In accordance, Brown et
al reaffirms this with a plausible explanation suggesting that
the inclusion of a conduit into the lumen results in
deposition of platelets and white blood cells that prompts
the consequent stenosis at the distal conduit anastomosis.
This occurs because the xenogenic tissue retains residual
antigenticity where both class I and II major
histocomaptibilty complex (MHC) residual antigens can
remain active.22
Various authors also believe that suture technique is
an important factor in preventing stenosis, with one
suggesting the use of a continuous suture with every third
stitch locked posteriorly and an interrupted suture
anteriorly.22 Also distal conduit anastomosis is advised to be
towards the left pulmonary artery as it prevents contact
between the lesser curvature of the ascending aorta and
distal Contegra anastomosis, which may potentially induce
conduit narrowing.1,23 The valve should also be kept as
distal as possible from the RV anastomosis. We advise that
the hood be kept reasonably wide, but avoid a balloon hood
as it leads to loss of energy of the ejected blood.

Conclusion
In conclusion, the Contegra is a promising easily
available substitute to the pulmonary homograft. The early
and intermediate results obtained at our institution are in
accordance with results found at other institutions where the
conduit has been deployed. However further studies need to
be carried out to determine long-term results in Pakistan.
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